First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
JCI Insight · 2023
DOI: 10.1172/jci.insight.158798 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2023. Verfasst von Maria V Guijarro und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology. Hauptthemen laut MEDLINE: Folic Acid Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, University of Florida.
Abstract (Originalsprache)
Although thymidylate synthase (TYMS) inhibitors have served as components of chemotherapy regimens, the currently available inhibitors induce TYMS overexpression or alter folate transport/metabolism feedback pathways that tumor cells exploit for drug resistance, limiting overall benefit. Here we report a small molecule TYMS inhibitor that i) exhibited enhanced antitumor activity as compared with current fluoropyrimidines and antifolates without inducing TYMS overexpression, ii) is structurally distinct from classical antifolates, iii) extended survival in both pancreatic xenograft tumor models and an hTS/Ink4a/Arf null genetically engineered mouse tumor model, and iv) is well tolerated with equal efficacy using either intraperitoneal or oral administration. Mechanistically, we verify the compound is a multifunctional nonclassical antifolate, and using a series of analogs, we identify structural features allowing direct TYMS inhibition while maintaining the ability to inhibit dihydrofolate reductase. Collectively, this work identifies nonclassical antifolate inhibitors that optimize inhibition of thymidylate biosynthesis with a favorable safety profile, highlighting the potential for enhanced cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology.
- Department of Medicinal Chemistry, and.
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA.
- Department of Biological Chemistry, Faculty of Exact and Natural Sciences, University of Buenos Aires, and.
- Institute of Biological Chemistry of the Faculty of Exact and Natural Sciences (IQUIBICEN) CONICET, University City, Pab. II (CE1428EHA), Buenos Aires, Argentina.
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- University of Florida
- Florida Department of Health
Zitieren
APA
Guijarro, M. V., Kellish, P. C., Dib, P. E., Paciaroni, N. G., Nawab, A., Andring, J., Kulemina, L., Borrero, N. V., Modenutti, C., Feely, M., Nasri, E., Seifert, R. P., Luo, X., Bennett, R. L., Shabashvili, D., Licht, J. D., McKenna, R., Roitberg, A., Huigens, R. W., …, & Zajac-Kaye, M. (2023). First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival. JCI Insight. https://doi.org/10.1172/jci.insight.158798
Vancouver
Guijarro MV, Kellish PC, Dib PE, Paciaroni NG, Nawab A, Andring J, et al. First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival. JCI Insight. 2023. doi:10.1172/jci.insight.158798
BibTeX
@article{Guijarro2023,
author = {Guijarro, Maria V and Kellish, Patrick C and Dib, Peter E and Paciaroni, Nicholas G and Nawab, Akbar and Andring, Jacob and Kulemina, Lidia and Borrero, Nicholas V and Modenutti, Carlos and Feely, Michael and Nasri, Elham and Seifert, Robert P and Luo, Xiaoping and Bennett, Richard L and Shabashvili, Daniil and Licht, Jonathan D and McKenna, Robert and Roitberg, Adrian and Huigens, Robert W and Kaye, Frederic J and Zajac-Kaye, Maria},
title = {First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival},
journal = {JCI Insight},
year = {2023},
doi = {10.1172/jci.insight.158798}
}
EUVIMED